ProteoDesign Competitors

Our people are our strength. And together with over 54,000 colleagues, we're creating the next breakthrough in the world of healthcare and innovation for both humans and animals. Are you ready to join us? #LifeForward Privacy Notice: https://www.boehringer-ingelheim.com/privacy-notice Imprint: https://www.boehringer-ingelheim.com/imprint

Bio-Rad provides the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. For more than 70 years we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of almost 8,000 employees and a network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.

Fraudulent Recruitment Advisory: Biocon and its subsidiaries never charge candidates any fee at any stage of recruitment. Learn how to identify and report fraudulent job offers: https://www.biocon.com/fraudulent-recruitment-advisory/ Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth.